Recce Pharmaceuticals Statistics
Total Valuation
RECEF has a market cap or net worth of 121.02 million. The enterprise value is 121.08 million.
| Market Cap | 121.02M |
| Enterprise Value | 121.08M |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 288.37M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +33.81% |
| Shares Change (QoQ) | +6.97% |
| Owned by Insiders (%) | 24.80% |
| Owned by Institutions (%) | 14.84% |
| Float | 201.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.58 |
| PB Ratio | -60.48 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.62 |
| EV / Sales | 22.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.02 |
Financial Position
The company has a current ratio of 1.86
| Current Ratio | 1.86 |
| Quick Ratio | 1.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.53 |
| Interest Coverage | -16.87 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -135.80% |
| Return on Invested Capital (ROIC) | -293.44% |
| Return on Capital Employed (ROCE) | -324.67% |
| Weighted Average Cost of Capital (WACC) | 5.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.80 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.33% in the last 52 weeks. The beta is 0.21, so RECEF's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | -63.33% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 3,178 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RECEF had revenue of 4.92 million and -14.05 million in losses. Loss per share was -0.06.
| Revenue | 4.92M |
| Gross Profit | -1.93M |
| Operating Income | -13.38M |
| Pretax Income | -14.05M |
| Net Income | -14.05M |
| EBITDA | -13.33M |
| EBIT | -13.38M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 7.01 million in cash and 7.06 million in debt, with a net cash position of -54,289.
| Cash & Cash Equivalents | 7.01M |
| Total Debt | 7.06M |
| Net Cash | -54,289 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -2.00M |
| Book Value Per Share | -0.01 |
| Working Capital | 3.45M |
Cash Flow
In the last 12 months, operating cash flow was -13.40 million and capital expenditures -17,273, giving a free cash flow of -13.42 million.
| Operating Cash Flow | -13.40M |
| Capital Expenditures | -17,273 |
| Free Cash Flow | -13.42M |
| FCF Per Share | n/a |
Margins
Gross margin is -39.12%, with operating and profit margins of -271.76% and -285.37%.
| Gross Margin | -39.12% |
| Operating Margin | -271.76% |
| Pretax Margin | -285.37% |
| Profit Margin | -285.37% |
| EBITDA Margin | -270.81% |
| EBIT Margin | -271.76% |
| FCF Margin | n/a |
Dividends & Yields
RECEF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.81% |
| Shareholder Yield | -33.81% |
| Earnings Yield | -11.61% |
| FCF Yield | -11.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RECEF has an Altman Z-Score of -10.7 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.7 |
| Piotroski F-Score | 2 |